ERBB2 and neoplasm: The binding of anti-HER2 VHH-FcK to HER2 almost matched that of Herceptin, and anti-HER2 VHH-FcK showed higher affinity for tumor cell in vitro; this is suggestive of its potential as an alternative therapeutic approach for HER2-positive tumors [18].